SymbioCellTech (SCT) raised $2.5M from H2M Capital Partners and angel investors. This is the second seed-stage round of funding for SCT. To date, the company has raised over $5.6M towards the development of its novel technologies for the cure of insulin-dependent diabetes mellitus.
